Managing Director, Longitude Capital
Marc Galletti is a founder and Managing Director of Longitude Capital. He focuses on investments in medical technology and specialty pharmaceuticals, including drug-device combinations. From 2003 to 2006, Mr. Galletti was a Senior Vice President of Pequot Ventures where he worked in the life sciences practice.
Prior to Pequot, Mr. Galletti worked at Amerindo Investment Advisors and Vector Fund Management where prior venture capital investments included Align Technology (NASDAQ: ALGN), CancerVax (acquired by Micromet), Eyetech Pharmaceuticals (NASDAQ: OSIP) and Theravance (NASDAQ: THRX). Mr. Galletti has also worked in the Global Healthcare Investment Banking Group at J.P. Morgan & Co. Mr. Galletti began his life sciences industry career 16 years ago at APM, a management consultancy dedicated to improving operations performance within large acute-care hospitals.
Mr. Galletti currently serves on the boards of Ajax Vascular, Aptus Endosystems, Sympara Medical and Twelve. He has also been involved with prior investments in Ablation Frontiers (acquired), Altiva Corporation (acquired), Facet Solutions (acquired), MAP Pharmaceuticals (NASDAQ: MAPP, acquired), Prestwick Pharmaceuticals (acquired), Sadra Medical (acquired), and Threshold Pharmaceuticals (NASDAQ: THLD).
Mr. Galletti also sits or has sat on advisory boards for the Innovation and New Ventures Office at Northwestern University, the Program for Biomedical Engineering at Brown University and AdvaMed. Mr. Galletti holds an M.B.A. from the Kellogg School of Management at Northwestern University and an A.B. from Princeton University.